EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act): Epigenomics AG Announces Capital Increase

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Restructuring & Recapitalisations/Company Information/molecular
diagnostics 20.12.2012

Not for distribution in the United States

Berlin, Germany, December 20, 2012 - Today the Executive Board of
Epigenomics AG, Berlin, Germany (Frankfurt Prime Standard: ECX; ISIN:
DE000A1K0516), with the approval of the Supervisory Board, has taken
the decision to implement an increase of the issued share capital by
utilization of authorised capital. The capital increase shall be
carried out by way of a rights issue against cash contributions. It
shall be structured in such a manner that the gross proceeds
generated under the capital increase will amount to up to just under
EUR5,000,000 in order to make use of the available exemption from the
publication of a prospectus under German securities laws.

In early January 2013, the Supervisory and Executive boards of the
Company plan to resolve the details of the capital increase, in
particular the maximum number of new shares and the subscription
ratio, which will then be published by way of an ad hoc announcement
without undue delay. Publication of the subscription offer and
beginning and end of the subscribtion period will subsequently take
place in line with German market practice.

The new shares will first be offered to the shareholders of the
Company. Shares not taken up by sharesholders might subsequently be
offered in a private placement to institutional investors.

Epigenomics AG intends to use the net proceeds from the offering to
finance its current operations and to build and strengthen the
distribution capacities for its products.

- End of Ad hoc -

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a
solicitation of an offer to purchase securities in the United States.
The shares of Epigenomics AG (the "Shares") have not been registered
under the U.S. Securities Act of 1933, as amended (the "Securities
Act") and may not be offered or sold in the United States unless
registered under the Securities Act or pursuant to an exemption from
such registration. There will be no public offering of the Shares in
the United States and the Shares will not be registered under the
Securities Act.

Contact:

Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386
antje.zeise@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English